The incident occurred inside the Oval Office as President Trump unveiled his ‘TrumpRx’ initiative—an effort to make GLP-1 drugs for obesity and diabetes more affordable. Findlay, who was standing behind the President, suddenly lost balance and collapsed. Dr. Mehmet Oz, head of the U.S. Centers for Medicare and Medicaid Services (CMS), quickly intervened and caught him before he hit the ground.
White House medical staff rushed to assist Findlay, and members of the press were escorted out while first aid was administered. Officials later confirmed that his condition was stable, and the event resumed shortly afterward.
Findlay serves as the Global Brand Director at Novo Nordisk, overseeing global marketing and product planning from the company’s Basel office in Switzerland. A biochemist by training, he previously helped manage supply chain issues related to Norditropin, one of the firm’s major products.
During the press briefing, President Trump announced that under the new ‘TrumpRx’ program, oral GLP-1 drugs will cost $149 per month (about Rs12,500), while injectable versions will be priced at $245 per month (around Rs20,500). The initiative, which will launch through a dedicated website next year, aims to make obesity and diabetes treatments more accessible across the country.
The President emphasized that lowering drug prices is a key goal of his administration, calling it “a breakthrough for millions of Americans struggling with chronic conditions.” Industry leaders from Novo Nordisk and Eli Lilly were present at the event, marking one of the most significant collaborations between the pharmaceutical sector and the Trump administration to date.
2.jpg)
